WO2009145456A3 - 헤테로사이클 유도체 - Google Patents

헤테로사이클 유도체 Download PDF

Info

Publication number
WO2009145456A3
WO2009145456A3 PCT/KR2009/001659 KR2009001659W WO2009145456A3 WO 2009145456 A3 WO2009145456 A3 WO 2009145456A3 KR 2009001659 W KR2009001659 W KR 2009001659W WO 2009145456 A3 WO2009145456 A3 WO 2009145456A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic derivatives
medicaments
preparation
uric acid
relates
Prior art date
Application number
PCT/KR2009/001659
Other languages
English (en)
French (fr)
Other versions
WO2009145456A2 (ko
Inventor
안성오
박찬희
임준환
이순옥
이경준
조성욱
고광석
한선영
이원일
Original Assignee
주식회사 씨앤드씨신약연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK09754921.6T priority Critical patent/DK2266989T3/en
Priority to ES09754921.6T priority patent/ES2552311T3/es
Priority to CA2718709A priority patent/CA2718709C/en
Priority to SI200931323T priority patent/SI2266989T1/sl
Priority to AU2009252166A priority patent/AU2009252166B9/en
Priority to JP2011502853A priority patent/JP5314123B2/ja
Priority to BRPI0909691-4A priority patent/BRPI0909691B1/pt
Priority to EP09754921.6A priority patent/EP2266989B1/en
Priority to CN200980113926.9A priority patent/CN102015726B/zh
Priority to NZ587880A priority patent/NZ587880A/en
Application filed by 주식회사 씨앤드씨신약연구소 filed Critical 주식회사 씨앤드씨신약연구소
Priority to MX2010010366A priority patent/MX2010010366A/es
Priority to PL09754921T priority patent/PL2266989T3/pl
Priority to EA201071144A priority patent/EA018521B1/ru
Priority to KR1020107021818A priority patent/KR101250297B1/ko
Priority to US12/935,478 priority patent/US8394792B2/en
Publication of WO2009145456A2 publication Critical patent/WO2009145456A2/ko
Publication of WO2009145456A3 publication Critical patent/WO2009145456A3/ko
Priority to ZA2010/06475A priority patent/ZA201006475B/en
Priority to IL208203A priority patent/IL208203A/en
Priority to HK11102459.7A priority patent/HK1148283A1/xx
Priority to HRP20151098TT priority patent/HRP20151098T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

본 발명은 헤테로사이클 유도체에 관한 것으로, 보다 상세하게는, 뇨산과 관련된 질병을 치료하는 의약의 제조에 유용한 신규한 헤테로사이클 유도체에 관한 것이다.
PCT/KR2009/001659 2008-03-31 2009-03-31 헤테로사이클 유도체 WO2009145456A2 (ko)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MX2010010366A MX2010010366A (es) 2008-03-31 2009-03-31 Derivados heterociclicos.
ES09754921.6T ES2552311T3 (es) 2008-03-31 2009-03-31 Derivados heterocíclicos
SI200931323T SI2266989T1 (sl) 2008-03-31 2009-03-31 Heterociklični derivati
AU2009252166A AU2009252166B9 (en) 2008-03-31 2009-03-31 Heterocyclic derivatives
JP2011502853A JP5314123B2 (ja) 2008-03-31 2009-03-31 複素環誘導体
BRPI0909691-4A BRPI0909691B1 (pt) 2008-03-31 2009-03-31 Composto derivado de heterociclo, método para preparar um composto, e, composição farmacêutica
EP09754921.6A EP2266989B1 (en) 2008-03-31 2009-03-31 Heterocyclic derivatives
PL09754921T PL2266989T3 (pl) 2008-03-31 2009-03-31 Pochodne heterocykliczne
NZ587880A NZ587880A (en) 2008-03-31 2009-03-31 Fused morpholine derivatives
DK09754921.6T DK2266989T3 (en) 2008-03-31 2009-03-31 Heterocyclic derivatives
CA2718709A CA2718709C (en) 2008-03-31 2009-03-31 Heterocyclic derivatives
CN200980113926.9A CN102015726B (zh) 2008-03-31 2009-03-31 杂环衍生物
EA201071144A EA018521B1 (ru) 2008-03-31 2009-03-31 Гетероциклические производные
KR1020107021818A KR101250297B1 (ko) 2008-03-31 2009-03-31 헤테로사이클 유도체
US12/935,478 US8394792B2 (en) 2008-03-31 2009-03-31 Heterocyclic derivatives
ZA2010/06475A ZA201006475B (en) 2008-03-31 2010-09-09 Heterocyclic derivatives
IL208203A IL208203A (en) 2008-03-31 2010-09-16 Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
HK11102459.7A HK1148283A1 (en) 2008-03-31 2011-03-11 Heterocyclic derivatives
HRP20151098TT HRP20151098T1 (hr) 2008-03-31 2015-10-19 Heterocikliäśki derivati

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0030067 2008-03-31
KR20080030067 2008-03-31

Publications (2)

Publication Number Publication Date
WO2009145456A2 WO2009145456A2 (ko) 2009-12-03
WO2009145456A3 true WO2009145456A3 (ko) 2010-01-21

Family

ID=41377713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001659 WO2009145456A2 (ko) 2008-03-31 2009-03-31 헤테로사이클 유도체

Country Status (24)

Country Link
US (1) US8394792B2 (ko)
EP (1) EP2266989B1 (ko)
JP (1) JP5314123B2 (ko)
KR (1) KR101250297B1 (ko)
CN (1) CN102015726B (ko)
AU (1) AU2009252166B9 (ko)
BR (1) BRPI0909691B1 (ko)
CA (1) CA2718709C (ko)
DK (1) DK2266989T3 (ko)
EA (1) EA018521B1 (ko)
ES (1) ES2552311T3 (ko)
HK (1) HK1148283A1 (ko)
HR (1) HRP20151098T1 (ko)
HU (1) HUE026261T2 (ko)
IL (1) IL208203A (ko)
MX (1) MX2010010366A (ko)
MY (1) MY155517A (ko)
NZ (1) NZ587880A (ko)
PL (1) PL2266989T3 (ko)
PT (1) PT2266989E (ko)
SI (1) SI2266989T1 (ko)
TW (2) TWI613203B (ko)
WO (1) WO2009145456A2 (ko)
ZA (1) ZA201006475B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
US20130090334A1 (en) * 2011-10-05 2013-04-11 Hoffmann-La Roche Inc Azabenzoxazine derivatives as crac modulators
EP2808018B1 (en) * 2012-01-27 2018-03-14 Teijin Pharma Limited Therapeutic agent for diabetes
US20140034475A1 (en) * 2012-04-06 2014-02-06 Deka Products Limited Partnership Water Vapor Distillation Apparatus, Method and System
JP5805613B2 (ja) * 2012-11-16 2015-11-04 株式会社神戸製鋼所 改質石炭の製造方法及び改質石炭製造装置
CN103936762B (zh) * 2013-01-17 2016-02-24 上海汇伦生命科技有限公司 吗啉并喹啉类化合物，其制备方法和用途
CN103664764A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-氨基-2-羟基吡啶的制备方法
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
SG11201609483YA (en) * 2014-05-13 2016-12-29 Teijin Pharma Ltd Novel crystalline polymorphs of pyridine derivative and method for producing the same
AU2015373089B2 (en) 2014-12-29 2020-02-20 Dethree Res. Lab. Inc. URAT1 inhibitor
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
CA3018115A1 (en) 2015-12-28 2017-07-06 Shanghai Fochon Pharmaceutical Co., Ltd. Indolizine derivatives, composition and methods of use
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108084186B (zh) 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CA3061301C (en) * 2017-05-25 2022-05-31 Jw Pharmaceutical Corporation Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
WO2018237370A1 (en) 2017-06-23 2018-12-27 Accro Bioscience Inc. HETEROARYL COMPOUNDS AS INHIBITORS OF THE NECROSIS, COMPOSITION AND METHOD OF USE THEREOF
CN109111464B (zh) * 2017-06-23 2021-02-26 爱科诺生物医药股份有限公司 一种具有细胞坏死抑制活性的杂环化合物
JP7266901B2 (ja) 2018-01-19 2023-05-01 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 複素環式化合物、調製方法及びその医薬的な応用
CN108558906A (zh) * 2018-05-21 2018-09-21 日照市普达医药科技有限公司 一种治疗白内障药物苯并吩噁嗪类化合物及其制备方法
JP2022537291A (ja) * 2019-06-17 2022-08-25 フォチョン・ファーマシューティカルズ・リミテッド ヘテロ環式誘導体及びその使用
CA3174831A1 (en) * 2020-06-04 2021-12-09 Beigene, Ltd. Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as iap antagonists
CN111841896B (zh) * 2020-08-06 2022-10-18 武汉工程大学 一种苯并杂环羟肟酸类捕收剂及其制备方法和应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010670A1 (en) * 2004-11-29 2007-01-11 Japan Tobacco Inc. Nitrogen-containing fused ring compounds and use thereof
WO2007089034A1 (en) * 2006-02-02 2007-08-09 Mitsubishi Tanabe Pharma Corporation Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002220389A (ja) * 2001-01-26 2002-08-09 Hokko Chem Ind Co Ltd ピリジルベンズオキサジン誘導体、除草剤および中間体
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
US20060177646A1 (en) * 2005-02-09 2006-08-10 Detlef Burgard Method for producing shatterproof glass panels and casting resin molding
WO2007093507A1 (en) * 2006-02-13 2007-08-23 F. Hoffmann-La Roche Ag Heterobicyclic sulfonamide derivatives for the treatment of diabetes
US7960377B2 (en) 2008-03-28 2011-06-14 Cara Therapeutics, Inc. Substituted pyridoxazines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010670A1 (en) * 2004-11-29 2007-01-11 Japan Tobacco Inc. Nitrogen-containing fused ring compounds and use thereof
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
WO2007089034A1 (en) * 2006-02-02 2007-08-09 Mitsubishi Tanabe Pharma Corporation Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds

Also Published As

Publication number Publication date
BRPI0909691A8 (pt) 2018-01-02
IL208203A0 (en) 2010-12-30
CA2718709A1 (en) 2009-12-03
ES2552311T3 (es) 2015-11-27
HUE026261T2 (en) 2016-06-28
PL2266989T3 (pl) 2016-04-29
WO2009145456A2 (ko) 2009-12-03
AU2009252166B2 (en) 2013-10-10
IL208203A (en) 2016-06-30
DK2266989T3 (en) 2015-11-23
CN102015726B (zh) 2014-07-23
MY155517A (en) 2015-10-30
EP2266989B1 (en) 2015-09-02
BRPI0909691B1 (pt) 2021-07-20
KR101250297B1 (ko) 2013-04-03
US8394792B2 (en) 2013-03-12
HRP20151098T1 (hr) 2016-01-01
AU2009252166A1 (en) 2009-12-03
SI2266989T1 (sl) 2015-12-31
PT2266989E (pt) 2015-11-23
AU2009252166B9 (en) 2014-02-13
EP2266989A2 (en) 2010-12-29
KR20110005688A (ko) 2011-01-18
HK1148283A1 (en) 2011-09-02
NZ587880A (en) 2012-06-29
TWI500622B (zh) 2015-09-21
JP2011516468A (ja) 2011-05-26
TW201522347A (zh) 2015-06-16
EA201071144A1 (ru) 2011-06-30
TWI613203B (zh) 2018-02-01
EP2266989A4 (en) 2011-10-12
EA018521B1 (ru) 2013-08-30
US20110028467A1 (en) 2011-02-03
TW201000488A (en) 2010-01-01
JP5314123B2 (ja) 2013-10-16
ZA201006475B (en) 2011-10-26
CA2718709C (en) 2016-08-09
CN102015726A (zh) 2011-04-13
BRPI0909691A2 (pt) 2015-08-04
MX2010010366A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
WO2009145456A3 (ko) 헤테로사이클 유도체
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2008033562A3 (en) Kinase inhibitor compounds
WO2010141796A3 (en) PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
WO2009139817A3 (en) Crystalline pharmaceutical and methods of preparation and use thereof
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2008104306A3 (de) Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung
WO2009140624A3 (en) Glucokinase activators
WO2009108383A3 (en) Substituted xanthine derivatives
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2008017346A3 (de) Ascorbinsäurederivate, verwendung zur funktionalisierung von matrices
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2011006935A3 (en) Tetrazole derivatives
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
WO2008131946A3 (de) Substituierte amid-derivate
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980113926.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09754921

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 587880

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2718709

Country of ref document: CA

Ref document number: 12010502092

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/010366

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009252166

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009754921

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107021818

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010004552

Country of ref document: MY

Ref document number: 2011502853

Country of ref document: JP

Ref document number: 12935478

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 6179/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009252166

Country of ref document: AU

Date of ref document: 20090331

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201071144

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0909691

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100924